• 1
    Meeuwis KA, Melchers WJ, Bouten H, et al. Anogenital malignancies in women after renal transplantation over 40 years in a single center. Transplantation 2012; 93: 914922 [Comparative Study].
  • 2
    Park ST, Song MJ, Park JS, Hur SY, Lee CW. Incidence and clinicopathologic behavior of uterine cervical carcinoma in renal transplant recipients. World J Surg Oncol [Clinical Trial Comparative Study] 2011; 9: 72.
  • 3
    Paternoster DM, Cester M, Resente C, et al. Human papilloma virus infection and cervical intraepithelial neoplasia in transplanted patients. Transplant Proc 2008; 40: 18771880.
  • 4
    Patel HS, Silver AR, Levine T, Williams G, Northover JM. Human papillomavirus infection and anal dysplasia in renal transplant recipients. Br J Surg 2010; 97: 17161721.
  • 5
    Meeuwis KA, van Rossum MM, Hoitsma AJ, de Hullu JA. (Pre)malignancies of the female anogenital tract in renal transplant recipients. Transplantation 2011; 91: 810.
  • 6
    Mochizuki K, Goda T, Yamauchi K. Gene expression profile in the liver of Rana catesbeiana tadpoles exposed to low temperature in the presence of thyroid hormone. Biochem Biophys Res Commun 2012; 420: 845850.
  • 7
    Kwak EJ, Julian K. Human papillomavirus infection in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4): S151S160.
  • 8
    Dillner J, Kjaer SK, Wheeler CM, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, vaginal intraepithelial neoplasia, anogenital warts: Randomised controlled trial. BMJ 2010; 341: c3493.
  • 9
    Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 19281943.
  • 10
    FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 19151927.
  • 11
    Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE. Human papillomavirus genotype distributions: Implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009; 101: 475487. [Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural]
  • 12
    Valles X, Murga GB, Hernandez G, et al. High prevalence of human papillomavirus infection in the female population of Guatemala. Int J Cancer 2009; 125: 11611167.
  • 13
    Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer 2007; 121: 621632.
  • 14
    Munoz N, Manalastas R Jr, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11 16, 18) recombinant vaccine in women aged 24–45 years: A randomised, double-blind trial. Lancet 2009; 373: 19491957.
  • 15
    Avery RK, Michaels M. Update on immunizations in solid organ transplant recipients: What clinicians need to know. Am J Transplant 2008; 8: 914.
  • 16
    Pastrana DV, Buck CB, Pang YY, et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2004; 321: 205216 [Comparative Study Research Support, U.S. Gov't, P.H.S.].
  • 17
    Opalka D, Lachman CE, MacMullen SA, et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003; 10: 108115.
  • 18
    Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 2006; 24: 55715583 [Clinical Trial, Phase II Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't].
  • 19
    Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 2011; 364: 401411.
  • 20
    Manuel O, Humar A, Berutto C, et al. Low-dose intradermal versus intramuscular trivalent inactivated seasonal influenza vaccine in lung transplant recipients. J Heart Lung Transplant 2011; 30: 679684.
  • 21
    Birdwell KA, Ikizler MR, Sannella EC, et al. Decreased antibody response to influenza vaccination in kidney transplant recipients: A prospective cohort study. Am J Kidney Dis 2009; 54: 112121.
  • 22
    Versluis DJ, Beyer WE, Masurel N, Wenting GJ, Weimar W. Impairment of the immune response to influenza vaccination in renal transplant recipients by cyclosporine, but not azathioprine. Transplantation 1986; 42: 376379.
  • 23
    FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis 2007; 196: 14381446.
  • 24
    Wilkin T, Lee JY, Lensing SY, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 2010; 202: 12461253.
  • 25
    Levin MJ, Moscicki AB, Song LY, et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr 2010; 55: 197204.
  • 26
    Weinberg A, Song LY, Saah A, et al. Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children. J Infect Dis 2012; 206: 13091318.
  • 27
    Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years. Hum Vaccin 2009; 5: 705719.
  • 28
    Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years. Hum Vaccin 2011; 7: 13591373.